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Abstract
Background Clear-cell renal cell carcinoma (ccRCC) is
one of the most common types of kidney cancer in adults;
however, its causes are not completely understood. The
study was designed to filter the key pathways and genes
associated with the occurrence or development of ccRCC,
acquaint its pathogenesis at gene and pathway level, to
provide more theory evidence and targeted therapy for
ccRCC.
Methods Gene set enrichment analysis (GSEA) and meta-
analysis (Meta) were used to screen the critical pathways
and genes which may affect the occurrence and progression
of ccRCC on the transcription level. Corresponding path-
ways of significant genes were obtained with the online
website DAVID (http://david.abcc.ncifcrf.gov/).
Results Thirty seven consistent pathways and key genes
in these pathways related to ccRCC were obtained with
combined GSEA and meta-analysis. These pathways were
mainly involved in metabolism, organismal systems, cel-
lular processes and environmental information processing.
Conclusion The gene pathways that we identified could
provide insight concerning the development of ccRCC.
Further studies are needed to determine the biological
function for the positive genes.
Keywords Clear-cell renal cell carcinoma
(ccRCC)  Gene set enrichment analysis 
Meta-analysis  Key pathways
Introduction
Renal cell carcinoma (RCC) is one of the most common
genitourinary malignancies, accounting for about 3 % of
all cancers worldwide [1]. Clear cell renal cell carcinoma
(ccRCC) is the most common histological type of renal cell
carcinoma, also called conventional RCC, which represents
75–80 % of RCC. The male/female ratio is approximately
2:1 [2]. Initial treatment is most commonly a radical or
partial nephrectomy and remains the mainstay of curative
treatment [3]. Where the tumor is confined to the renal
parenchyma, the 5-year survival rate is 60–70 %, but this is
lowered considerably where metastases have spread. It is
relatively resistant to radiation therapy and chemotherapy,
although some cases respond to immunotherapy.
After the completion of the Human Genome Project,
advances in microarray technology led to global gene
expression profiling of ccRCC [4–6]. Microarray tech-
nology profiles the expression levels of thousands of
genes simultaneously, providing a snapshot of transcript
levels in the cells/tissues being studied; it is a powerful
tool to study ccRCC. All microarray data are available
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from the Gene Expression Omnibus (GEO) public data-
base at NCBI [7]. However, the large amounts of data
acquired must be reduced or ‘translated’ to a smaller set
of genes representing meaningful biological differences
between control and test systems and validated in an
experimental or clinical setting. It is a challenge to ana-
lyze such high information from microarray datasets to
identify molecular pathways and key genes deregulated in
ccRCC. To resolve this conflict, Subramanian describes a
method gene set enrichment analysis (GSEA) which has
been recognized as a breakthrough for the gene set and
functional pathways analysis [8]. GSEA is a method that
allows us to search the key genes and pathways associ-
ated with the occurrence and development of disease by
analyzing diverse experimental datasets. However, the
difference of platforms, the sample capacity and the
standardization affect the result more or less. Meta-
analysis of microarray data can be a better way to solve
the problem of poor reproducibility and reliability [9]. In
our study, after a standardized microarray preprocessing
for all the expression datasets, GSEA and a meta-analysis
were used to detect the mixing pathways and key genes
which can provide the theoretical basis to the further
perception of the biological mechanism of ccRCC.
Materials and methods
Data collection
We used clear cell renal cell carcinoma as the keywords
and set the limit of study type expression profiling by array
and a species limit of humans to search GEO (http://www.
ncbi.nlm.nih.gov/geo/) for the relevant gene datasets.
Search results provided 2,762 identified datasets involved
in ccRCC. Studies that met all of the following criteria
were included: (1) the data were about genome-wide RNA
expression; (2) the complete microarray raw or normalized
data were effective; (3) the data provided a comparison of
renal tissue between ccRCC patients and normal controls
relatively; (4) datasets contained more than three samples;
(5) the raw data were expressed as CEL files. Finally, there
were three gene expression datasets which met the selec-
tion criteria (Table 1).
Gene set enrichment analysis
The category version 2.10.1 package was used to perform
with GSEA. General statistical analysis and computing was
processed in the R statistical programming language [10].
The Robust Multichip Averaging (RMA) [11] algorithm in
the affy conductor package [12] was used for each
affymetrix raw dataset to calculate background-adjusted,
normalized and log2 probe set intensities. The only genes
we selected should have been mapped to an explicit KEGG
pathway for the purpose of analyzing the GSEA and meta-
analysis further [13]. We performed pathway analysis of
each dataset independently. The measure of variability was
within the interquartile range (IQR) and a cut-off was set
up to remove IQR values under 0.5 for all the remaining
genes. If one gene was targeted for multiple probe sets, we
retained the probe set with the largest variability. Genes in
each pathway went through the Student’s t test, and each
pathway’s p value was obtained in the permutation test
with 1,000 times. The p value was not more than 0.05.
Meta-analysis
To obtain the differentially expressed genes from the
remaining genes of each dataset above, meta-analysis was
carried out in SAS 9.13. The following formula was






(K is the number of the datasets).
To calculate p value of each gene, and retained the
genes with p \ 0.05. Significant genes were used to obtain




According to the inclusion criteria, we obtained three data-
sets in the end. Tissues used to extract the total RNA were
matched pairs from clear cell renal cell carcinoma and
Table 1 Characteristics of datasets selected in the studies
GEO accession Contributor Years Chip Experimental design Probs Source Disease Normal
GSE781 Lenburg ME 2003 HG-U133A Paired, tissues 22,283 Homo sapiens 7 7
GSE6344 Gumz ML 2007 HG-U133A Paired, tissues 22,283 Homo sapiens 10 10
GSE36895 Pen˜a-Llopis S 2012 HG-U133_Plus_2 Paired, tissues 54,675 Homo sapiens 23 23
Paired = compare clear cell renal carcinomas to normal controls from the same patients with clear cell renal carcinoma
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normal tissue adjacent to renal cell carcinoma. The fuhrman
grade of ccRCC was no more than three. Due to the samples
used, genomic profiling were matched pairs. It reduced the
influence of multiple factors on GSEA and Meta-analysis,
ensuring the reliability of the obtained conclusion.
The three inclusion datasets contained 40 ccRCC cases
and 40 controls. GSEA method was used separately on
each dataset to find the significantly changed genes and the
significant co-pathways. After GSEA analysis, 8,506 sig-
nificantly changed genes were screened out from the three
gene expression microarray datasets. Overlap existed in the
up-regulated and down-regulated pathways. There were
fourteen mixing pathways including 206 up-regulated and
253 down-regulated pathways from three datasets. Detailed
information about the analysis results is shown in Table 2.
Meta-analysis
To further identify the results above, meta-analysis was
used to detect differentially expressed genes between two
experimental groups. We got the p value for each gene
based on unpaired t test. A total of 1,150 significant genes
were detected (p \ 0.05). Furthermore, the Database for
Annotation, Visualization and Integrated Discovery
(DAVID) (http://david.abcc.ncifcrf.gov/) was utilized for
the annotation of these genes. We imported the official
gene symbols of 1,150 genes into the gene functional
classification tool of DAVID. In order to identify biologi-
cally relevant molecular networks of these genes, KEGG
(http://www.genome.jp/kegg/), a distinct pathway analysis
tools of bioinformatics endowed with comprehensive
knowledgebase was used. There were 1,038 genes identi-
fied by KEGG. In total, 48 KEGG pathways were detected.
More details were shown in Table 3.
The results of GSEA and meta-analysis
To search the intersection pathways, a comparative anal-
ysis was made subsequently between the significant com-
mon pathways of GSEA and meta-analysis. At last, 37
consistent pathways and significant genes (p \ 0.05) in
these pathways were obtained. These pathways mainly
concerned metabolism, organismal systems, cellular pro-
cesses, environmental information processing, and human
diseases. The details are shown in Table 4.
Discussion
Clear cell renal cell carcinoma is one of the most common
types of kidney cancer in adult; however, its causes are not
completely understood. The selection of differentially
expressed genes and consistent pathways helps us to
explore their underlying molecular mechanisms, thereby
providing insights into biological function. Single gene-
marker-based approaches can fail to detect transcriptional
programs that are distributed across an entire network of
genes are yet subtle at the level of individual gene [15].
Genome-wide microarrays can locate gene families and
pathways which show a consistent alteration in a disease
state. Pathway analysis is a valid method to reduce a major
deviation and can obtain interesting common genes and
pathways by mixing differently expressed genes from dif-
ferent datasets.
Some studies have been published. The study of Tun
et al. [16] used gene expression profiling of early-stage
ccRCC combined with a comprehensive bioinformatics
analyses to reveal the significant pathway and transcription
factors which take effect in the development of ccRCC.
Meanwhile, Maruschke et al. [17] used microarray
expression analysis to determine 16 gene sets that distin-
guish expression profiles from grade 1 and grade 3 tumor
tissues based on MSigDB data bank analysis. The two
studies above were single dataset analysis. However, multi-
microarray dataset analysis for the development of ccRCC
was rare. This study uses three datasets based on a novel
GSEA carried out by KEGG dataset and meta-analysis
approach to identify the common significant genes and
genetic pathways with p \ 0.05 associated ccRCC. And
our findings suggest that most genes and pathways
involved in ccRCC are the same according to their func-
tional classification. In this study, we discussed several
differentially expressed pathways and genes among cross-
ing pathways which suggest the role of these pathways and
genes in ccRCC based on their functional classification.
Metabolism pathways
The metabolism pathways in our study were predominantly
focused on carbohydrate metabolism, lipid metabolism,
energy metabolism, amino acid metabolism, metabolism of
other amino acids, metabolism of cofactors and vitamins.
Table 2 Summary of each












GSE781 7 7 2,689 73 57
GSE6344 10 10 2,644 68 96
GSE36895 23 23 3,173 65 100
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Table 3 Common significant pathways were obtained from 3 clear
cell renal carcinoma tissue datasets by meta-analysis
Pathway
entry










































































map05219 Bladder cancer 0.00611 17 Down
map05212 Pancreatic cancer 0.00669 25 Down














































map05214 Glioma 0.02205 21 Down
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ccRCC is increasingly being recognized as a metabolic
disease. Numerous studies have shown a significant asso-
ciation between body mass index, obesity and the devel-
opment of kidney cancer [18]. In a case–control study from
Iowa, diets richest in animal and saturated fats, oleic acid
and cholesterol were associated with statistically signifi-
cant increases in RCC (1.9–2.6-fold, depending on the
factor) [19]. These metabolic abnormalities provide pro-
tection for the tumor but also may provide a source of
vulnerability and therapeutic opportunity. Citrate cycle
(TCA cycle) discovered in this study belongs to Carbo-
hydrate metabolism; it is part of a metabolic pathway
coupled to mitochondrial oxidative phosphorylation that
converts nutrients to energy in aerobic cells. Recently,
heterozygous germline mutations in fumarate hydratase
(FH) or succinate dehydrogenase (SDH) of the TCA cycle
have been shown to predispose individuals to tumors [20].
SDHB/C/D is the key gene in the Citrate cycle and oxi-
dative phosphorylation pathway in our article. SDH is one
of the seven known kidney cancer genes involved in
pathways that respond to metabolic stress and/or nutrient
stimulation [21]. Targeting the fundamental metabolic
abnormalities in kidney cancer provides a unique oppor-
tunity for the development of more effective forms of
therapy for this disease. Recently, early-onset renal tumors
have been found to develop in individuals with germ line
SDHB mutations [22, 23]. In preclinical models, increased
succinate has been shown to inhibit HIF prolyl hydroxylase
and affect HIF stability [24]. HIF can strengthen the
expression of vascular endothelial growth factor (VEGF),
glucose transcript factor 1 (GLUT-1) and glycolytic
enzyme in the downstream target genes; promote the
generation of blood vessels and energy metabolism of
cells; and possibly play an important role in the developing
progress in the excessive expression of malignant tumor
[25, 26].
Cellular processes and cell communication
Focal adhesion pathway (Fig. 1) in our result belongs to
cellular processes and cell communication. In cell biol-
ogy, focal adhesions (cell–matrix adhesions or FAs) are
specific types of large macromolecular assemblies through
which both mechanical force and regulatory signals are
transmitted. Cell–matrix adhesions play essential roles in
important biological processes including cell motility, cell
proliferation, cell differentiation, regulation of gene
expression and cell survival [27]. Tumor epithelial and
endothelial cells require attachment to the extracellular
matrix (ECM) for survival; on loss of adhesion, they
undergo anoikis [28, 29]. Quinazoline-based drugs trigger
anoikis in renal cancer cells by targeting the focal adhe-
sion survival signaling. This potent antitumor action
against human RCC suggests a novel quinazoline-based
therapy targeting renal cancer [30]. VEGFA/B/C (marked
by red stars in Fig. 1) is significant gene in focal adhesion
pathway. The role of VEGF in particular has been
explored as a key factor in the pathogenesis of RCC.
VEGF functions to increase vascular permeability, induce
endothelial cell proliferation and migration, and promote
endothelial cell survival [31]. Furthermore, VEGF recep-
tor expression has been observed in RCC cells, suggesting
that VEGF may also serve as an autocrine stimulus in
RCC [32]. The high VEGF expression in RCC is the
direct result of inactivation of the Von Hippel–Lindau
tumor suppressor gene (VHL). Data suggest that VHL
inactivation occurs in the majority of ccRCC [33]. Ther-
apeutic targeting of VEGF in RCC has strong biologic
rationale. Substantial clinical activity has been reported in
clinical trials with VEGF-targeting agents [34, 35]. Fur-
ther investigation is needed to optimally use these agents
for maximal clinical benefit.
Environmental information processing
Extracellular matrix–receptor interaction and cell adhesion
molecule (CAM) pathways were in this classification. They
are all about signaling molecules and interaction. The
extracellular matrix (ECM) consists of a complex mixture
of structural and functional macromolecules and serves an
important role in tissue and organ morphogenesis and in
the maintenance of cell and tissue structure and function
[36]. There is close connection between ECM–receptor
interaction and focal adhesion pathway, which is also a
significant pathway. At the cell–extracellular matrix con-
tact points, specialized structures are formed and termed
focal adhesions, where bundles of actin filaments are
anchored to transmembrane receptors of the integrin family
through a multi-molecular complex of junctional plaque
proteins [37]. There is increasing evidence that certain
integrins associate with receptor tyrosine kinases (RTKs) to
activate signaling pathways that are necessary for tumor
invasion and metastasis [38]. Zhou et al. [39] found that
multiple canonical cancer-associated signaling pathways
including focal adhesion, cell cycle and ECM–receptor
interaction were significantly more likely to be disrupted in
ccRCC than expected by chance. This is consistent with the
results of our study.
CD47 is a key gene in ECM–receptor interaction path-
way, which is involved in the increase in intracellular
calcium concentration that occurs upon cell adhesion to
extracellular matrix. As has been found by other investi-
gators, CD47 over expression may be associated with ferric
nitrilotriacetate-induced renal cortical tubular damage and
regeneration that lead to a polycystic state, and with tumor
progression and metastasis of the induced RCCs [40].
550 Int Urol Nephrol (2014) 46:539–553
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Other pathways and genes
Human diseases and organismal systems are the two
remaining classifications associated with ccRCC. Path-
ways such as type I diabetes mellitus, epithelial cell
signaling in helicobacter pylori infection, bladder cancer,
systemic lupus erythematosus and so on all belonged to
the classification of human diseases. They are mainly
about endocrine and metabolic diseases, neurodegenera-
tive diseases, infectious diseases, cancers, immune dis-
eases and cardiovascular diseases. Some diseases above
belong to endocrine or immune system organic system in
the classification of organismal systems. Most of genes
in these pathways can be enriched in the above path-
ways. HLA-DQB1 appears in 8 pathways in human
diseases, organismal systems and environmental infor-
mation processing classification is an important gene for
ccRCC, and this has widely been reported in the litera-
ture. Patients with RCC whose tumors did not express
HLA-DQA1 or HLA-DQB1 molecules demonstrated
poor clinical response [41]. EGFR and VEGFA/B/C
expression in human disease pathways play an important
regulatory role in tumor angiogenesis, invasion and
metastasis. Based on the EGFR/VEGF target in
the treatment of cancer is the hot spot in drug research
[42].
Conclusion
The pathogenesis of ccRCC is quite complicated. It is effec-
tive to identify differentially expressed genes and deduce their
underlying molecular pathways based on gene set enrichment
analysis and meta-analysis. The significant genes and path-
ways were mainly focused on metabolism, cellular processes
and cell communication, environmental information pro-
cessing, human diseases and organismal systems. They may
have some connections with ccRCC. Furthermore, we verified
some of the results by searching the literature in the discussion
section. The conclusion is relatively reliable and can be used
to guide further study. Further experiments are needed to
verify specific links between these results and ccRCC.
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Fig. 1 Focal adhesion pathway (the chart is from the KEGG database, wp \ 0.05, genes symbolized byw and correlation p values can be found
in map04510 of Table 4)
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